Quantcast

Becton, Dickinson Focuses on Medication Management, Stock Up


Shutterstock photo

Becton, Dickinson and Company BDX , popularly known as BD, recently enhanced the medication management process through technological innovation. The company introduced innovative platforms like BD HealthSight viewer, BD Pyxis ES software and BD Alaris infusion solutions. These promise inventory optimization, availability, solid clinician productivity and complete medication safety to patients.

BD HealthSight viewer is a web-based pharmacy operations dashboard that leverages on BD Pyxis and BD Alaris infusion systems. The BD Pyxis ES has been exclusively designed to enhance clinician productivity.

In short, the platforms particularly focus on medication availability and efficiency. This is done by monitoring the devices and reporting the infusion status continuously.

What is Medication Management?

Reports suggest that medication management involves a comprehensive review of medical prescriptions by planning short and long-term medication treatments. The review includes monitoring the safety and efficiency of the medicinal procedures and patient education.

A report by Markets And Markets reveals that the global medication management market is expected to see a CAGR of 13% to 15% in the 2014-to-2019 period to reach a worth of $1,624.9 million.

Other than BD, companies like McKesson Corporation MCK and Cerner Corporation CERN are leading players in the medication management space.

Shares Rise

Shares of BD have inched up 0.6% to $219.07 since the news release. BD has a long-term expected earnings growth rate of 12%.

Year to date, BD has had an impressive run on the bourses. The company has returned 35.6%, comparing favorably with the broader industry 's gain of 16.2%. In fact, the current return is higher than the S&P 500's addition of 16.2%.

The stock has a Zacks Rank #3 (Hold).

BD Portfolio Solid

Meanwhile, management at BD has been focusing on strengthening its portfolio for long. Recently, the company signed an agreement with Fresenius Medical Care FMS to distribute sodium chloride saline. The addition of sodium chloride to BD's Medication Management portfolio is likely to prove beneficial.

The other major launches include UltraTouch push-button blood collection set, Veritor Plus and BD MAX assays.

The latest research on clinical instruments in the life sciences segment and Pyxis ES and Neopak in the medical segment is notable.

Within the genomics business, BD recently expanded its portfolio through the launch of BD Rhapsody, a new single cell platform for RNA expression analysis.

Wall Street's Next Amazon

Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time. It's a once-in-a-generation opportunity to invest in pure genius.

Click for details >>


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Cerner Corporation (CERN): Free Stock Analysis Report

Fresenius Medical Care Corporation (FMS): Free Stock Analysis Report

Becton, Dickinson and Company (BDX): Free Stock Analysis Report

McKesson Corporation (MCK): Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.



This article appears in: Investing , Business , Stocks
Referenced Symbols: CERN , FMS , BDX , MCK


More from Zacks.com

Subscribe






Zacks.com
Contributor:

Zacks.com

Equity Research








Research Brokers before you trade

Want to trade FX?





Find a Credit Card

Select a credit card product by:
Select an offer:
Search
Data Provided by BankRate.com